Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RIST 4721

Drug Profile

RIST 4721

Alternative Names: AZD-4721; RIST-4721

Latest Information Update: 24 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer Aristea Therapeutics; AstraZeneca; Pfizer
  • Class Anti-inflammatories; Antibronchitics; Skin disorder therapies; Small molecules
  • Mechanism of Action Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Behcet's syndrome; Chronic obstructive pulmonary disease; Hidradenitis suppurativa; Inflammatory bowel diseases; Palmoplantar pustulosis

Most Recent Events

  • 10 Feb 2023 Discontinued - Phase-II for Hidradenitis suppurativa in Canada (PO)
  • 10 Feb 2023 Discontinued - Phase-II for Palmoplantar pustulosis in Poland, Hungary, Czech Republic, United Kingdom, Canada (PO)
  • 10 Feb 2023 Aristea Therapeutics withdraws a phase II trial in Familial Mediterranean Fever (In adults, In elderly) in Turkey (PO) prior to enrolment due to safety findings in other ongoing phase II trials (NCT05448391)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top